Aclaris Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aclaris Therapeutics, Inc. - overview
Established
2012
Location
Wayne, PA-Pennsylvania, US
Primary Industry
Biotechnology
About
Founded in 2012 and based in Pennslyvania, US, Aclaris Therapeutics, Inc. operates as a biotechnology company that develops small molecule therapies for patients suffering from immuno-inflammatory conditions. The company also operates Confluence Discovery Technologies, Inc. as an indirect, wholly-owned subsidiary that provides full-service drug discovery and early development services for pharma and biotech companies.
In October 2015, Aclaris Therapeutics, Inc. was listed on the Nasdaq under the symbol ACRS for an initial public offering of 5 million shares priced at USD 11 apiece. In November 2024, Aclaris Therapeutics, Inc. raised USD 80 million in PPIPE funding led by returning investor Vivo Capital, with participation from new Rock Springs Capital, Adage Capital Management, Decheng Capital, Logos Capital, and Samsara BioCapital.
Other returning investors Forge Life Science Partners, RA Capital Management, and other unspecified investors also participated in the round. As part of the transaction, the company agreed to sell 35. 5 million shares of common stock purchase at USD 4. 9 per share, for gross proceeds of approximately USD 80 million.
The company's R&D (research and development) team utilizes KINect, a drug discovery platform that enables the generation of diversified immuno-inflammatory therapeutics to attach human kinases with adenosine triphosphate (ATP) site cysteines (human cysteinome) for the treatment of patients with aesthetic, medical dermatology, and immuno-inflammatory diseases. In October 2019, EPI Health acquired RHOFADE, an oxymetazoline hydrochloride cream for rosacea from Aclaris Therapeutics, Inc. As a contract research organization, the company's revenue is generated by providing research partnership and development services of specialty pharmaceuticals for biotechnology companies. The company revenue growth rate decreased by 58.
11 percent from USD 10. 09 million in FY 2018 to USD 4. 23 million in FY 2019. The company continues to develop a multi-state portfolio of drug candidates through KINect, the R&D engine exploring protein kinase regulation for the potential treatment of immuno-inflammatory diseases, such as the oral approach on moderate to severe RA (Rheumatoid Arthritis).
Current Investors
Vivo Capital, Adage Capital Management, Decheng Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.aclaristx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aclaris Therapeutics, Inc. - timeline of key events
Aclaris Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 1,683,000 | 10,091,000 | 4,227,000 | 6,482,000 | 6,761,000 | 29,752,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 499.6% | (58.1%) | 53.3% | 4.3% | 340.1% | - | - | - |
| EBITDA (USD) | (20,577,000) | (48,447,000) | (72,021,000) | (133,535,000) | (104,649,000) | (49,588,000) | (88,800,000) | (89,057,000) | - | - | - |
| Operating Income (USD) | (20,667,000) | (48,567,000) | (72,423,000) | (135,414,000) | (111,058,000) | (50,912,000) | (89,723,000) | (89,854,000) | - | - | - |
| Operating Margin | - | - | (4303.2%) | (1341.9%) | (2627.3%) | (785.4%) | (1327.1%) | (302.0%) | - | - | - |
| % EBITDA Margin | - | - | (4279.3%) | (1323.3%) | (2475.7%) | (765.0%) | (1313.4%) | (299.3%) | - | - | - |
| NET Income (USD) | (20,563,000) | (48,079,000) | (68,523,000) | (132,738,000) | (161,354,000) | (51,015,000) | (90,865,000) | (86,908,000) | - | - | - |
| % Net Margin | - | - | (4071.5%) | (1315.4%) | (3817.2%) | (787.0%) | (1344.0%) | (292.1%) | - | - | - |
Aclaris Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Aclaris Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Aclaris Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Aclaris Therapeutics, Inc. | - | ||||||||
| Venture Debt | Completed | Aclaris Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Aclaris Therapeutics, Inc. | - |
Displaying 1 - 5 of 12
Aclaris Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.